Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

CATALYST PHARMACEUTICALS INC (CPRX)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/20/2018 04/23/2018 04/24/2018 04/25/2018 04/26/2018 Date
2.51(c) 2.56(c) 2.58(c) 2.64(c) 2.89(c) Last
377 954 295 326 593 127 848 768 2 101 152 Volume
-1.18% +1.99% +0.78% +2.33% +9.47% Change
More quotes
Financials (USD)
Sales 2018 1,46 M
EBIT 2018 -36,8 M
Net income 2018 -36,4 M
Debt 2018 -
Yield 2018 -
Sales 2019 25,4 M
EBIT 2019 -12,2 M
Net income 2019 -11,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 182x
Capi. / Sales2019 10,4x
Capitalization 265 M
More Financials
Company
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company.It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder.The... 
More about the company
Surperformance© ratings of Catalyst Pharmaceuticals I
Trading Rating : Investor Rating :
More Ratings
Latest news on CATALYST PHARMACEUTICALS I
04/25CATALYST PHARMACEUTICALS : Announces Enrollment of First Patient in Phase 3 Tria..
AQ
04/24CATALYST PHARMACEUTICALS : Introduces New Corporate Website
AQ
04/20CATALYST PHARMACEUTICALS : Announces Enrollment of First Patient in Phase 3 Tria..
AQ
04/19CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
AQ
04/19Catalyst Pharmaceuticals Announces Enrollment of First Patient in Phase 3 Tri..
GL
04/03CATALYST PHARMACEUTICALS : Announces Submission of New Drug Application for Fird..
AQ
03/30CATALYST PHARMACEUTICALS : Announces Submission of New Drug Application for Fird..
AQ
03/29CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Financial Statements a..
AQ
03/29CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
AQ
03/29Catalyst Pharmaceuticals Announces Submission of New Drug Application for Fir..
GL
More news
Sector news : Bio Therapeutic Drugs
04/26GILEAD SCIENCES : The Million Dollar Cancer Treatment No One Knows How to Pay fo..
DJ
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
04/19Novartis CEO feels heat on U.S. generics, Cosentyx drop
RE
04/17GE rides gene therapy wave with ready-made viral drug factories
RE
04/12GSK slims portfolio with sale of rare disease gene therapy drugs
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/26ORIONS Money Stocks: $CPRX should be $4.38 in 2-3 weeks $GLD $G..
1
04/26$CPRX breakout alert $4.50 here we come $GLD $GOLD $SLV
1
04/26$CPRX should be $4.38 in 2-3 weeks $AAPS 2.59 Target $GLD $GOLD..
2
04/26ORIONS Money Stocks: $CPRX should be $4.38 in 2-3 weeks  
04/26$SSC Target ? $3.40 $CPRX ready $APPS BOOMING $GLD $GOLD $SLV ..
1
More tweets
Qtime:111
News from SeekingAlpha
04/19Enrollment underway in late-stage study of Catalyst Pharma's Firdapse in subt.. 
04/04Midday Gainers / Losers (4/4/2018) 
04/04HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am (04/04/2018) 
04/033 THINGS IN BIOTECH, APRIL 2 : Catalyst Pharm Goes, Pfizer Flows, MediciNova Woe.. 
03/31WEEK 14 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
Chart CATALYST PHARMACEUTICALS I
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Technical analysis trends CATALYST PHARMACEUTICALS I
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 6,25 $
Spread / Average Target 137%
EPS Revisions
Managers
NameTitle
Patrick J. McEnany Chairman, President & Chief Executive Officer
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer & Head-Regulatory Affairs
Philip H. Coelho Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST PHARMACEUTICALS INC-34.02%265
GILEAD SCIENCES1.51%94 816
VERTEX PHARMACEUTICALS3.88%39 523
REGENERON PHARMACEUTICALS-17.01%33 601
GENMAB18.71%12 384
BEIGENE LTD (ADR)69.87%9 095